Over the past decade there have been significant advances in the treatment of acute myelogenous leukemia (AML). The introduction of intensive induction and post-remission chemotherapy programs, together with the improvement in supportive care, have resulted in a probability of long-term survival in 30%–50% of children with AML [1–4]. In 1982 the AIEOP (Italian Pediatric Hematology-Oncology Association) cooperative group began a multicenter prospective trial for pediatric AML in order to establish the value of a polychemotherapeutic regimen consisting of intensive induction followed by intensive consolidation and continuation chemotherapy.
Toxicity Leukemia Oncol Etoposide Cytosine
This is a preview of subscription content, log in to check access
Creutzig U, Ritter J, Riehm H et al. (1985) Improved treatment results in childhood acute myelogenous leukemia: a report of the German Cooperative Study AML-BFM-78. Blood 65: 298–304PubMedGoogle Scholar
Weinstein HJ, Mayer RJ, Rosenthal DS et al. (1983) Chemotherapy for acute leukemia in children and adults: VAPA update. Blood 62: 315–319PubMedGoogle Scholar
Gale RP, Foon KA (1987) Therapy of acute myelogenous leukemia. Semin Hematol 24: 40–54PubMedGoogle Scholar
Kalwinsky D, Mirro J, Schell M et al. (1988) Early intensification of chemotherapy for childhood acute non-lymphoblastic leukemia: improved remission induction with a five drug regimen including Etoposide. J Clin Oncol 6: 1134–1143PubMedGoogle Scholar